CAIX imaging of the indeterminate renal mass
Scans find small kidney lumps all the time and cannot tell which are cancer. Up to one in five that are surgically removed turn out to be harmless. A scan that recognises the commonest kidney cancer would spare those operations, and it needs no drug to be useful.
Overview
This is the cleanest standalone diagnostic case in the field: the scan answers a question on its own, with no therapy dependency. Between 12.8% and 40% of surgically resected small renal masses are benign depending on size, and no imaging technique reliably defines histological subtype before surgery.
The lead agent has the evidence. 89Zr-girentuximab (TLX250-CDx, Zircaix) reported phase 3 ZIRCON results in Lancet Oncology in October 2024: 300 patients dosed, 284 evaluable, sensitivity 85.5% and specificity 87.0% for clear cell renal cell carcinoma, with no safety signals. The BLA was accepted with priority review and a PDUFA date of 27 August 2025, but the FDA issued a complete response letter on chemistry, manufacturing and controls rather than efficacy or safety; the sponsor has since reported agreement on remediation after Type A meetings. It remains unapproved anywhere.
Behind it sit peptide and small-molecule CAIX ligands with same-day kinetics: 68Ga-DPI-4452 has FDA Fast Track designation and first-in-human data, and a technetium-99m CAIX peptide and a gallium-68 CAIX agent have small first-in-human cohorts. Chinese academic work includes a 47-patient 68Ga-NY104 cohort. The opportunity split is therefore sharp: the antibody owns the evidence and the regulatory queue, while the unmet need for a same-day, widely distributable agent is unmet by definition because no peptide has a phase 3.
When CT or MRI finds an indeterminate renal mass, nothing tells the clinician whether it is clear cell renal cell carcinoma before committing the patient to surgery, biopsy or surveillance, and up to a fifth of resected small masses prove benign.
- The category may be closed before a second entrant arrives: if the manufacturing remediation succeeds, an approved antibody becomes the standard of care and the bar for a peptide rises to non-inferiority against an approved product.
- A same-day ligand has to match an 85% and 87% benchmark set in a 284-patient phase 3, which is an expensive trial to run second.
- Reimbursement for avoided surgery requires a health-economic case, not just accuracy.
- Whether the manufacturing complete response letter is resolved and TLX250-CDx is approved, which would reset the benchmark from unmet need to non-inferiority.
- Accuracy data from any same-day CAIX peptide, particularly 68Ga-DPI-4452 after its Fast Track designation.
- Any European filing, since no EMA submission for the antibody has been found.
The five domains of a radiopharmaceutical due-diligence review, adapted from the Fryback-Thornbury hierarchy of diagnostic efficacy. Each carries the state of the public evidence and the fact behind it, not a score out of five: a single total hides the reason and stops telling candidates apart. Domains marked as carrying most weight are the ones that decide the case at this asset's stage.
CAIX is expressed in over 90% of clear cell renal cell carcinoma through constitutive HIF-1 activity after VHL loss, and is essentially absent from normal renal parenchyma.
A completed phase 3 of 300 dosed and 284 evaluable patients published in Lancet Oncology, the only phase 3 diagnostic dataset for any CAIX agent.
Sensitivity 85.5% (95% CI 81.5 to 89.6) and specificity 87.0% (81.0 to 93.1) for clear cell renal cell carcinoma in ZIRCON.
No safety signals in the phase 3; girentuximab whole-body effective dose is reported at 0.57 plus or minus 0.08 mSv/MBq.
The pathway is proven to the point of a priority-review BLA, then blocked: the FDA issued a complete response letter on chemistry, manufacturing and controls, not on efficacy or safety, and the product is approved nowhere.
Red, amber or green on each review category, each with its reason, so an obvious no-go takes seconds rather than a meeting.
The proven agent is a zirconium-89 antibody imaged days after injection; the same-day peptides have small cohorts and no accuracy dataset.
Up to 15 to 20% of resected small renal masses are benign and no imaging test defines subtype, so the scan prevents operations rather than selecting drugs.
The antibody and its phase 3 dataset are owned, and several peptide and small-molecule CAIX ligands are already claimed by companies with first-in-human data; entering now means designing around a crowded space.
Standalone by construction: reimbursement rests on avoided surgery, not on another company's drug approval, which is the strongest commercial position a diagnostic can have.
Zirconium-89 is cyclotron-made with limited distribution; a gallium-68 or fluorine-18 ligand would remove that constraint.
A phase 3 agent sits in the regulatory queue and at least three peptide or small-molecule programmes have human data, so the field is contested at every stage.
- Telix Pharmaceuticalsfiled, not approved
89Zr-girentuximab (TLX250-CDx, Zircaix): phase 3 ZIRCON published, BLA accepted with priority review, complete response letter on manufacturing August 2025.
https://pubmed.ncbi.nlm.nih.gov/39270701/ - ITM Isotope Technologies Munichearly clinical
68Ga-DPI-4452, a small peptide CAIX ligand with FDA Fast Track designation in November 2025 and a three-patient first-in-human report in the Journal of Nuclear Medicine.
https://jnm.snmjournals.org/ - Philochemfirst-in-human
99mTc-PHC-102 with a five-patient cohort, and 68Ga-OncoCAIX with a clinical trial application submitted.
https://www.philochem.ch/ - Chinese academic programmesearly clinical
68Ga-NY104, a CAIX agent with a 47-patient cohort.
Similar pages
not linked directly; found by shared links- Key paperZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma
Shares Zirconium-89 girentuximab, CAIX PET (89Zr-girentuximab), Immuno-PET, Zirconium-89.
- Trial89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Shares CAIX (carbonic anhydrase IX), Zirconium-89 girentuximab, Zirconium-89, Renal cell carcinoma.
- TrialZIRCON
Shares Zirconium-89 girentuximab, CAIX PET (89Zr-girentuximab), Zirconium-89, Renal cell carcinoma.
- PathwayVHL / HIF oxygen sensing
Shares CAIX (carbonic anhydrase IX), CAIX PET (89Zr-girentuximab), Zirconium-89, Renal cell carcinoma.
- IdeaCAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy
Shares CAIX (carbonic anhydrase IX), CAIX PET (89Zr-girentuximab), Zirconium-89, Renal cell carcinoma.
- OpportunityDLL3 imaging for small-cell lung cancer
Shares Immuno-PET, Zirconium-89, PET/CT, Gallium-68.
- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
- OpportunityCEACAM5 imaging for occult colorectal recurrence
Shares Immuno-PET, Technetium-99m, PET/CT, Gallium-68.